Moderna stock is trading -44.69% below its average target price of $47.7 after dropping -1.3% during today's morning session. Analysts are giving the Large-Cap Biotechnology company an average rating of hold and target prices ranging from $20.0 to $198.0 per share.
The stock has an unusually large proportion of its shares sold short at 21.6%, and a short ratio of 6.34. The company's insiders own 7.28% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 73.9% of Moderna's shares being owned by this investor type.
Institutions Invested in Moderna
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Vanguard Group Inc | 10% | 40,396,513 | $1,065,659,979 |
| 2025-03-31 | Blackrock Inc. | 7% | 27,181,154 | $717,038,819 |
| 2025-03-31 | BAILLIE GIFFORD & CO | 6% | 24,948,558 | $658,142,939 |
| 2025-03-31 | FMR, LLC | 5% | 21,130,029 | $557,410,147 |
| 2025-03-31 | State Street Corporation | 5% | 17,778,558 | $468,998,345 |
| 2025-03-31 | Geode Capital Management, LLC | 2% | 7,456,590 | $196,704,837 |
| 2025-03-31 | Morgan Stanley | 2% | 7,438,405 | $196,225,117 |
| 2025-03-31 | Theleme Partners LLP | 2% | 7,242,390 | $191,054,242 |
| 2025-03-31 | UBS Group AG | 2% | 6,377,537 | $168,239,420 |
| 2025-03-31 | Invesco Ltd. | 2% | 5,883,624 | $155,209,996 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Moderna.
